Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation

Journal article

Open access

Peer reviewed

Eleanor Higgins, Tariq Al Shehri, Maeve A McAleer, Niall Conlon, Conleth Feighery, Desa Lilic and Alan D Irvine

Journal of allergy and clinical immunology, Vol.135(2), pp.551-553.e3

01/02/2015

PMID: 25662309

Abstract

Candidiasis, Chronic Mucocutaneous - drug therapy

Candidiasis, Chronic Mucocutaneous - genetics

Heterozygote

Humans

Mutation

Protein Kinase Inhibitors - therapeutic use

Pyrazoles - therapeutic use

STAT1 Transcription Factor - genetics

Treatment Outcome

url

https://doi.org/10.1016/j.jaci.2014.12.1867View

Published (Version of record) Open

1 Record Views

Title: Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation
Creators - without role: Eleanor Higgins - St. James's Hospital
Tariq Al Shehri - University of Newcastle Australia
Maeve A McAleer - National Children’s Research Centre
Niall Conlon - St. James's Hospital
Conleth Feighery - St. James's Hospital
Desa Lilic - Newcastle University
Alan D Irvine - Trinity College Dublin
Publication Details: Journal of allergy and clinical immunology, Vol.135(2), pp.551-553.e3
Identifiers: 9921383008331
Academic Unit: King Saud Bin Abdulaziz University for Health Sciences
Language: English
Resource Type: Journal article